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Abstract 
The computational strategies like molecular docking, simulation, in silico ADMET and 
drug-likeness prediction were adopted to search potential compounds that can inhibit the effects 
of SARS-CoV-2. Considering the published literatures on medicinal importance, total 154 
phytochemicals with analogous structure from limonoids and triterpenoids were selected to 
search potential inhibitors for the five protein targets of SARS-CoV-2, i.e., 3CLpro (main 
protease), PLpro (papain like protease), SGp-RBD (spike glycoprotein-receptor binding domain), 
RdRp (RNA dependent RNA polymerase, ACE2 (angiotensin converting enzyme 2). Analyses 
of the in silico computational results and reported medicinal uses, the phytochemicals such as 7-
deacetyl-7-benzoylgedunin, epoxyazadiradione, limonin, maslinic acid, glycyrrhizic acid and 
ursolic acid were found to be effective against the target proteins of SARS-CoV-2. The protein-
ligand interaction study revealed that these phytochemicals bind at the main active site of the 
target proteins. Therefore, the core structure of these potential hits can be used for further lead 
optimization to design drugs for SARS-CoV-2. Also, the plants extracts like neem, tulsi, citrus 
and olives containing these phytochemicals can be used to formulate suitable therapeutics 
approaches in traditional medicines. 
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1. Introduction 
The ongoing research focused globally to formulate suitable therapeutic approaches to 
control the effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to 
human life that caused the disease COVID-19. The first patient infected with SARS-CoV-2 was 
detected in December, 2019 at Wuhan, China. Subsequently, the virus spread across 187 
countries and territories due to its high human to human contagious nature and infected 4006,257 
as of 11th May 2020 with a total death of 278,892 [1]. The uncontrolled spread pushed the World 
Health Organization (WHO) to declare the outbreak of SARS-CoV-2 as a public health 
emergency of international concern (PHEIC) on 30th Jan 2020, whereas a pandemic on 11th 
March 2020 [2]. Effective steps like identification of infected persons through rapid diagnosis, 
and quarantined them to stop further spread of the virus are underway to fight against this 
pandemic. However, the non-availability of medically proven efficacious drugs or vaccines is the 
main concern of COVID-19 pandemic [3]. Repurpose of some approved drugs like 
hydroxychloroquine, remdesivir, favipiravir, arbidol, hydroxychloroquine/azithromycin, 
lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta etc. are used, but 
despite some promising results further clinical results are required to examine their mechanisms 
of inhibition, efficacy and safety in the treatment of COVID-19 [4-8]. Therefore, both 
computational and experimental approaches are adopted to search suitable drugs from the library 
of FDI-approved drugs and also drugs under clinical trial but not yet approved to repurpose 
against the COVID-19. Simultaneously, the recent reports supporting the use of traditional 
medicines as adjuvant for treating COVID-19 [9-11] and therefore, efforts are also going to 
integrate the use of both western drugs and traditional medicines to formulate suitable 
therapeutic strategies. 
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 The computational approaches like dynamic simulations, molecular docking, drugs 
likeness prediction, in silico ADMET study etc. are valuable tools to screen potential 
drugs/molecules from various databases that contained in lakhs. The computational screening 
save both experimental cost and time in the field of drugs discovery. Considering the recent 
results of the use of traditional medicines in managing the epidemic of COVID-19 [9-11], our 
ongoing research is focused on to screen phytochemicals found mainly in the Indian medicinal 
plants with the important objectives: (i) to search phytochemicals that bind effectively at the 
active sites of the protein targets of SARC-VoV-2, (ii) to propose important hits that can be 
further investigated for lead optimization and drugs discovery, and (iii) to provide 
computational evidences for formulating Indian traditional medicines in controlling the spread 
and effects of SARC-VoV-2. Our literatures survey revealed that the triterpenoids like 3β-
friedelanol from Euphorbia neriifolia,  quinone-methide triterpenoids extracted from 
Tripterygium regelii (Celastraceae) and glycyrrhizin from Glycyrrhiza glabra are experimentally 
proven to inhibit the effects of SARS-CoV (first identified in Guangdong, China in 2002) [12-
15]. Also, our recent molecular docking studies of phytochemicals against the protein targets of 
SARS-CoV-2 supported the higher binding affinity towards limonin, a triterpenoid found in 
citrus [16].  
Considering the above facts, we selected 154 phytochemicals from limonoids and 
triterpenoids by considering their basic knowledge on medicinal importance and structural 
analogous to search potential hits for the five protein targets of SARS-CoV-2 i.e., 3CLpro (main 
protease), PLpro (papain like protease), SGp-RBD (spike glycoprotein-receptor binding domain), 
RdRp (RNA dependent RNA polymerase, ACE2 (angiotensin converting enzyme 2). The 
computational approaches like in silico ADMET, drugs likeness, simulations and molecular 
docking studies were performed to propose the potential hits from the 154 phytochemicals. 
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2. Experimental  
2.1. Compounds and proteins selection 
The selected 154 biologically important compounds from limonoids and triterpenoids 
were collected from various sources and screened to filter potential compounds that can inhibit 
the activity of SARS CoV-2. The SDF files of the selected phytochemicals were retrieved from 
EMBL-EBI (www.ebi.ac.uk/chebi/advancedSearchFT.do) and PUBCHEM 
(https://pubchem.ncbi.nlm.nih.gov/). The collected structures of the phytochemicals were further 
optimized by semi-empirical PM6 method coded in the computational program Gaussian 09W 
[17]. The optimized structures were converted to PDB file format by using the program 
GaussView 5.0. The crystallography structures of the SARS-CoV-2 protein targets (3CLpro, 
PDB ID: 6LU7; PLpro, PDB ID: 4MM3; RdRp, PDB ID: 6M71; SGp-RDB, PDB ID: 2ghv; 
ACE2, PDB ID: 6M17) were retrieved from the PDB database (www.rcsb.org).  
2.2. Molecular docking and simulations 
The molecular docking studies were carried out by using Autodock Vina1.1.2 [18], and 
the binding energies of the limonoids and triterpenoids were estimated towards SARS-CoV-2 
therapeutic targets. The proteins 3D structures retrieved from RCSB PDB databases, and some of 
the missing residues of the proteins were modelled using Swiss model online tools to generate 
the fine structures. The refined protein structures were analysed using the Ramachandran plot.  
Different conformations, hydrophobic sites are identified and analysed using BIOVIA Discovery 
studio visualization tool.  
The protein structure flexibility and dynamics simulations were performed using 
CABSflex2.0 online simulation tool with the default options [19]. The simulated model 
generated through trajectory clustering k-medoid method. This tool calculates the protein 
dynamic simulations at 10 ns, predicts fluctuations and protein aggregation propensity. 
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2.3. ADMET and drug-likeness prediction 
After the molecular docking analysis of 154 compounds with the five protein targets of 
SARS-CoV-2, the absorption, distribution, metabolism, elimination and toxicity (ADMET) of 
the 47 best dock scored limonoids and triterpenoids were further screened using online tool 
‘http://biosig.unimelb.edu.au/pkcsm/prediction’ to predict their important pharmacokinetic 
properties. ADMET properties include absorption: Caco-2 permeability, water solubility, human 
intestinal absorption, P-glycoprotein substrate, P-glycoprotein I and II inhibitors, skin 
permeability; Distribution: VDss (Volume of Distribution), Fraction unbound, Blood brain 
barrier (BBB) permeability, CNS permeability; Metabolism: Cytochrome P450 inhibitors, 
CYP2D6/CYP3A4 substrate; Excretion: renal OCT2 substrate, Drug total clearance. Toxicity: 
Rat LD50, AMES toxicity, T. pyriformis toxicity, Minnow toxicity, maximum tolerated dose, 
oral rat chronic toxicity, Hepatotoxicity, skin sensitization, hERG I and II inhibitors [20].  
Drug-likeness properties were predicted using the online tool molinspiration 
(https://www.molinspiration.com/cgi-bin/properties). Providing SMILES inputs of selected 
compounds into the tool calculated the LogP values to predict the molecular properties and 
bioavailability scores resulting in the drug likeness of the compound. Based on drug likeness and 
bioavailability capabilities, the potential compounds were finalized for further study. The 
calculations of LogP are based on the formula satisfying lipophilicity, hydrophobicity and 
polarity of the compound explains the ability of molecules that could bind to hydrophobic sites 
of target proteins [21].  
Lipophilicity = Hydrophobicity – Polarity 
Log P = aV + ʌ              (V=Molecular Volume, ʌ=Polarity term) 
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3. Results and discussion 
3.1. Selection of the phytochemicals 
Our recent molecular docking study on searching inhibitors for COVID-19 revealed that 
the phytochemicals limonin known for inhibiting the replication of retroviruses like HTLV-I and 
HIV-1 showed the higher dock score towards the three protein targets (spike glycoprotein, RdRp 
and ACE2) of SARS-CoV-2, and comparatively higher than the drug hydroxychloroquine [21]. 
Limonin, the highly oxygenated triterpenoid dilactone is the first isolated limonoids and till date 
more than 300 limonoids are isolated and characterized. The plants containing limonoids 
including the structural analogous triterpenoids, such as citrus, neem, basils and licorice etc., are 
reported for various pharmaceutical properties like antiviral, antifungal, antibacterial, anticancer 
and antimalarial, and also used routinely in the Indian traditional medicine (ayurveda) to treat 
various health problems. Therefore, a basic preliminary screening of phytochemicals from 
limonoids and triterpenoids were carried out based on the published literatures, and total 154 
phytochemicals were selected, and then studied against the five protein targets (3CLpro, PLpro, 
spike glycoprotein, RdRp and ACE2) of SARS-CoV-2 (Scheme 1).  
 
Scheme 1. Flow-chart showing the steps to screen phytochemicals for the COVID-19. 
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3.2. Molecular docking results 
The selected 154 phytochemicals were screened against the five important protein targets, 
i.e., Mpro or 3CLpro, PLpro, SGp-RBD, RdRp and ACE2 of SARS-CoV-2 by performing 
molecular docking analysis using the Autodock Vina computational program. The structural 
spike glycoprotein (S protein) of SARS-CoV-2 recognizes with the transmembrane protein of 
host cell receptor ACE2 [22,23]. This also internalizes the virus into the endosomes where the 
conformational changes take place in the spike glycoprotein. It acts as a viral fusion peptide that 
covers up S2 cleavage that occurs during virus endocytosis. Thereafter, RdRp facilitates the viral 
genome replication [24]. The main protease 3CLpro and PLpro act as proteases in the process of 
proteolysis of viral polyprotein into functional units [25]. In short, the SpG and ACE2 are 
collectively involved in disease establishment and 3CLpro, PLpro, RdRp involved in translation 
and replication lead to virus proliferation in the host cell. Therefore, these five proteins were 
considered as the therapeutic targets for the molecular docking with the selected 154 
phytochemicals. 
The dock score of the compounds against each protein are summarized in Table S1. The 
table of dock score of 154 phytochemicals against the five target proteins revealed that majority 
of the phytochemicals showed dock score higher than -6.5 Kcal/mol, and comparably higher 
dock score than the western drugs hydroxychloroquine and arbidol studied as a control. As the 
core part of all the compounds are similar, 20 compounds from each protein that showed the 
maximum dock score were selected for further screening (Table S2). Accordingly, total 47 
compounds were considered for further in silico ADMET and drug-likeness study.  
3.3. In silico ADMET and drug-likeness results  
The 47 compounds selected based on their higher dock score were screened further for in 
silico ADMET and drug-likeness study. Considering the computational prediction and the 
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available experimental evidences on their pharmaceutical properties, the best 6 compounds for 
each protein target (i.e., total 15 phytochemicals) were selected for protein-ligand interaction 
study to intendity the potential hits that bind at the catalytic sites of the respective protein (Table 
1). These 15 compounds are obeying ADMET limitations and drug likeness LogP values. These 
compounds satisfied the limitations of lipophilicity, hydrophobicity and polarity. These 
compounds drug-likeness properties screened based on miLogP (molinpiration LogP) values and 
TPSA (Molecular polar surface area) [26]. This study helps in screening out the best compound 
with drug-likeness and polarity of compound permeable in biological system. The results of 
ADMET properties are given in the supplementary data (Table S3). ADMET results are 
interpreted based on marginal values compared with resultant value as high caco-2 permeability 
predicted value >0.90, intestinal absorption less than 30% is considered as poorly absorbed, 
human VDss is low if it is below 0.71 L/kg and high value above 2.81L/kg, BBB permeability 
logBB > 0.3 considered as it cross BBB and logBB<-1 are poorly distributed. CNS permeability 
interpreted through logPS > -2 penetrate CNS and logPS < -3 as unable to penetrate. T. 
pyriformis toxicity predicted value > -0.5 ug/L considered as toxic and Minnow toxicity log 
LC50< -0.3 considered as high acute toxicity [27]. The most of the potent compounds finalised 
are found in the extracts of medicinal plants like neem, basil, licorice and citrus (Table 1).  
Table 1. List of potent phytochemicals screened based on in silico ADMET, drug-likeness and 
published pharmaceutical data. 
Compounds Sources Medicinal Properties miLogP TPSA Ref 
Corosolic acid  
Lagerstroemia 
speciosa 
Supress proliferation of cancer 
cells 5.87 77.75 28 
Glycyrrhizic acid Licorice 
Treats liver diseases, 
Anti HIV-1, SARS-CoV 1.97 267.04 29,30 
Maslinic acid Olives 
Anti-oxident, anti-inflammatory, 
weak inhibition to cytochrome 
P450 5.81 77.75 31 
2-
Hydroxyseneganolide 
Fruits of Khaya 
senegalensis 
Antifungal activity especially 
against botrytis cinerea 1.47 132.51 32 
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Oleanane 
woody 
angiosperms 
Antioxidant, anti-inflammatory, 
hepatoprotective, 
cardioprotective, antipruritic, 
spasmolytic, antiallergic, 
antimicrobial and antiviral effects 
and anti canceral especially breast 
cancer 8.86 0 33 
7-Deacetyl-7-
benzoylgedunin 
Neem 
(Azadirachta 
indica) 
Activity against HL60 leukemia 
cells 6.07 95.35 34 
Epoxyazadiradione 
Neem 
(Azadirachta 
indica) 
Plasmodium falciparum 
plasmepsin I inhibitor 3.66 86.11 35 
Limonoid Citrus Fruits 
 Inhibit the HIV 1 replication in 
cellular systems 2.53 104.58 36 
7-Deacetylgedunin 
Neem 
(Azadirachta 
indica) Antimalarial, anti-inflammatory 3.64 89.27 37 
Oleanolic acid 
Ocimum Sanctum 
(Basil) 
 Therapeutic potential for 
neurodegenerative diseases 6.72 57.53 38 
Ursolic acid 
Ocimum Sanctum 
(Basil) 
 Therapeutic potential for 
neurodegenerative diseases 6.79 57.53 39 
Limonin17 beta-
Dglucopyranoside Citrus Fruits 
 Inhibit colon adenocarcinoma cell 
proliferation through apoptosis -0.29 214.96 40 
Azadiradionolide 
Neem 
(Azadirachta 
indica) Apoptosis inducing activity 2.85 86.75 41 
Gedunin 
Neem 
(Azadirachta 
indica) Antiplasmodial 4.34 95.35 42 
Obacunone Citrus Fruits 
Represses solmonella pathogenity 
and also inhibits human colon 
cancer 3.8 95.35 43 
 
3.4. Protein-ligand interaction study 
3.4.1. Screening of inhibitors for main protease  
The main protease 3CLpro is a cysteine protease containing three domains, i.e., domains 
I (8-101 residues) and II (102-184 residues) with antiparallel -barrel structure and the domain 
III (201-303 residues) with five α-helices is linked to the domain II by a long loop (185-200 
residues) [44]. The catalytic dyad residues Cys145 and His41 are involved in substrate cleavage 
and present in the cleft between domain Ⅰ and Ⅱ. The enzyme active site consists of 6 subunits 
(S1-S6), the active site residues are 140-145 and 163-166 amino acids in the domain II. The best 
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6 compounds finalised based on the dock score with 3CLpro followed by in silico ADMET and 
drug-likeness are summarized in Table 2 along with the important molecular interactions.  
The main protease complex with the phytochemicals 7-deacetyl-7-benzoylgedunin is 
showing binding affinity at the catalytic dyad (Fig. 1 and Fig. S1). Catalytic dyad pocket shows 
ligand binds to Cys145 forming π-alkyl interaction and His41 forming π-cation interactions [44]. 
The 7-deacetyl-7-benzoylgedunin had shown dock score -9.1kcal/mol at the active site of 
3CLpro long loop region of domain Ⅱ (1)(2). The interaction study of 7-deacetyl-7- 
benzoylgedunin results in C-H bond interaction to Thr26 and showing unfavourable bond to 
Gln189 and His164. The closest VDW forces with the residues Glu166, Arg188, Leu167, 
Gln192, Thr190, Met49, Gly143, Thr25 and Asn142 of the domain II antiparallel -barrel 
structure. The protein structural simulation generated RMSF graph showing protein residues 
fluctuation and aggregation (Fig. S2). The fluctuated residues showing the hydrophobic cavities 
where substrate binding, catalytic functions took place. For 3CLpro simulation, some of the 
residues fluctuation impact of chain A (5-16, 46-56, 136-151, 165-178, 181-196, 241-260, 271-
286) and fluctuation impact showing ligand interactions at these residues. 
The phytochemicals glycyrrhizic acid showing highest dock score -9.3kcal/mol bind at 
the C terminal residues that are Asn274, Gly275, Leu286, Leu287, Asp289, Glu288, Arg131, 
Glu290, Asn238, Thr198, Tyr239, Leu272, Gln273 showing VDW forces and Tyr237, Lys137, 
Thr199 forming H bonding at the hydrophobic site containing largest ligand-binding cavity but 
the activity is unknown. Ursolic acid and oleanolic acid isolated from holy basil leaves are also 
effectively targeting the Mpro active sites forming hydrogen bonds to Lys137, Leu272 and 
closest non-covalent interactions with Thr199, Arg131, Leu287 residues with maximum binding 
energy -8.9 kcal/mol. Similarly, the interaction sites of other phytochemicals limonin and 
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obacunone binding at C terminal hydrophobic pocket are also summarized and compared (Table 
2). 
 
Fig. 1. (a) 2D animated pose between 7-deacetyl-7-benzoylgedunin and 3CLpro showing various 
non-covalent interactions, (b) 3D representation showing the position of 7-deacetyl-7-
benzoylgedunin within the hydrophobic cavity of 3CLpro. 
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Table 2. Screened phytochemicals used for protein-ligand interaction study against the main 
protease 3CLpro. 
Phytochemicals B.E. 
(Kcal/mole) 
Molecular interactions 
7-deacetyl-7-
benzoylgedunin -9.1 
A: C: Thr26, H: Glu166, VDW: Arg188, Leu167, Gln192, Thr190, Met49, 
Gly143, Thr25, Asn142, π-π: A: Pro168, Leu27, Cys145, Cationic: His41, 
Met165 
Glycyrrhizic 
acid -9.3 
A: H- Tyr237, Lys137, Thr199, C: Asp197 
VDW: Asn274, Gly275, Leu286, Leu287, Asp289, Glu288, Arg131, Glu290, 
Asn238, Thr198, Tyr239, Leu272, Gln273 
Limonin -8.7 
A: H: Thr199, C: Leu287 
VDW:Leu272, Tyr239, Tyr237, Asn238, Gly275, Met276, Leu286, Leu271, 
Lys137, Cationic: A: Arg131, Anionic : A: Asp289 
Oleanolic acid -8.9 
A: H- Lys137, Leu271, Leu272 
VDW:Gln273, Gly275, Met276, Leu287, Tyr239, Leu286, Thr199, Arg131, 
Asp197, Asn238, Tyr237 
Ursolic acid -8.9 
A: H: Lys137, Leu272,  
VDW: Asp197, Thr198, Arg131, Asp289, Thr199, Leu286, Tyr239, Leu287, 
Met276, Gly275, Leu271, Gln273, Tyr237 
Obacunone -8.7 
A: H- A: Met276, C: Gly275, π-π - Leu286 
VDW: Tyr237, Tyr239, Thr199, Ala285, Leu271, Leu272, Leu287, Asp289, 
Glu288. 
 
3.4.2. Screening of inhibitors for PLpro 
PLpro consists of four domains such as thumb, finger, palm and ubiquitin like domain. 
The active site located in between the thumb and palm domains [45]. The subunits consist of 
catalytic triad (Cys112, His273, Asp287), where the active site is located. PLpro NSP3 domain 
contains S2/S4 inhibitor binding sites. Therefore, the molecular screening of phytochemicals that 
docked at specific residues of S2/S4 site could inhibit the activity of PLpro [45]. The dock score 
along with the molecular interactions of the best 6 phytochemicals are summarized in Table 3. 
The protein-ligand interaction study revealed that the epoxyazadiradione binds exactly at 
the S2 active site of PLpro with the binding energy -8.4 kcal/mol. At the active site, the ligand 
targeted residues Gly164 and Tyr274 are forming H bond. Residues Pro248 and Pro249 forming 
π-alkyl interaction. Residues Leu163, Gln270, Tyr269, Met209, Thr302, Asp165, Tyr265, 
Cys271 and Gly272 are showing VDW interactions (Fig. 2 and Fig. S3). Epoxyazadiradione 
13 
 
binding at the pocket of catalytic triad (Cys112, His273, Asp287) residues can hindrance the 
enzymatic activity of PLpro [46,47]. Further, the MD simulations generated RMSF plot of PLpro 
showing available contacts to substrate at chain B (5-10, 170-185, 265-270) residues (Fig. S4). 
 
Fig. 2. (a) 2D animated pose between epoxyazadiradione and PLpro showing various non-
covalent interactions, (b) 3D representation showing the position of epoxyazadiradione within 
the hydrophobic cavity of PLpro. 
The protein-ligand interaction study of other best dock score phytochemicals revealed 
that the binding site are not at the catalytic triad. The NSP3 domain S4 subunit active site docked 
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with 7-deacetylgedunin showing -8.2 kcal/mol binding energy. Residues like Gln270, Lys158 
showing H bond and VDW forces observed at the residues Thr302, Pro249, Tyr265, Tyr269, 
Cys271, Asn268, Leu163, Glu162, Asp165 and Tyr274. One of the limonoid 7-deacetyl-7-
benzoylgedunin, which is a potent inhibitor of Mpro active site showing the maximum affinity to 
PLpro hydrophobic site but the activity of the site is not reported. This site forming H bond to 
Arg141, Gln134 and Glu125, C bond and VDW forces to Leu124, Gln122, Gln123, Val126, 
Lys127 and Glu135.  
Table 3. Screened phytochemicals used for protein-ligand interaction study against the PLpro. 
Phytochemicals B.E. 
(Kcal/mole) 
Molecular interactions 
Epoxyazadiradione -8.4 
B:H-Gly164,Tyr274,VDW:Leu163,Gln270,Tyr269,Met209, 
Thr302,Asp165,Tyr265, Cys271,Gly272,  π-π: Pro248,Pro249 
Glycyrrhizic acid -9.0 
B: H:  Leu76, Thr7, Asp77, Arg83, Asn157, Asn129, ASn178, B:His74,  
VDW: Phe80,Ala154,Gln175,His172,His176,Glu180,Phe70 
7-Deacetyl-7-
benzoylgedunin -8.3 
B: H- B: Arg141,Gln134, C-H- B: Glu125 
VDW: Leu124,Gln122,Gln123,Val126,Lys127,Glu135 
π-π - B: Tyr138 
Limonin -8.3 
B:H:Arg167,Gln175,VDW:Leu200,Gln233,Arg184,Tyr208,Leu186,  
Met209,Met207,Thr171.π-π - B: Val203, Anionic- B: Glu204 
7-Deacetylgedunin -8.2 
B:H:Gln270,Lys158,VDW:Thr302,Pro249,Tyr265,Tyr269, 
Cys271,Asn268,Leu163, Glu162,Asp165,Tyr274 
Obacunone -8.2 
B:H:Met209,Arg167,VDW:Leu200,Glu204,Gln175,Met207,Tyr208, 
Arg184,Leu186, Gln233 
 
3.4.3. Screening of inhibitors for RdRp (NSP12 domain) 
RdRp, the non-structural protein NSP12 is a replication tools plays a major role in 
transcription cycle of virus with the help of cofactors (NSP7, NSP8). So the primary target of the 
RdRp is NSP12, where the active sites are located. RdRp consists of NSP12-NSP7-NSP8 
domains, where the active site is in between the NiRAN domain -hairpin [49]. There are more 
than 80 phytochemicals showed activity against RdRp functional sites. We selected 6 
compounds based on the higher dock scores, known medicinal properties, in silico ADMET and 
drug likeness predictions. The interaction details of the top 6 ligands were given in the Table 4. 
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Limonin (furanolactones), a potent phytochemicals docked at the active site between NSP12-
NSP7 residues. Limonin is encapsulated within the receptor cavity showing hydrophobic surface 
and maximum binding energy -9.2kcal/mol (Fig. 3 and Fig. S5). RdRp substrate-binding site 
interacting with limonin formed H bond to Ser709, Lys714, Asp711, Thr710 maintaining strong 
affinity and that includes non-covalent VDW forces between ligand and Gln773, Gly774, 
Asn781, Lys780, Ser784, His133, Lys47, Asn138, Tyr129, Asp135, Thr710, Tyr32 in the active 
pocket. RdRp structural contacts in chain A: 31-45, 255-285, 419-459, 909, B chain: 103 and 
148-188 residues showing hydrophobic cavities, substrate binding sites involved in replication 
process and those are resembling in the RMSF plot (Fig. S6). 
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Fig. 3. (a) 2D animated pose between limonin and RdRp showing various non-covalent 
interactions, (b) 3D representation showing the position of limonin within the hydrophobic 
cavity of RdRp. 
Glycyrrhizic acid is also encapsulated in the receptor cavity with maximum binding 
energy -9.9kcal/mol and the site located between NiRAN domain and β-hairpin structure that 
polymerize 3ʹ end [49]. Glycyrrhizic acid could cause interference to β-hairpin polymerize 
activity due to its binding affinity at the active site residues Tyr129, Ser772, Asn781, Asn138 
and closest non-covalent interactions to Gln773, Lys714, Tyr32, Asp711, Ser784, Lys780, 
Gly774, Ser778, Ala706, Thr710, Asp135, His133, Cys139, Lys47. Other limonoids showing 
binding affinity to RdRp hydrophobic cavities are 7-deacetyl-7-benzoylgedunin, 7-
deacetylgedunin, limonin-17beta-D-glucopyranoside and obacunone (Table 4). 
Table 4. Screened phytochemicals used for protein-ligand interaction study against the RdRp. 
Phytochemicals B.E. 
(Kcal/mole) 
Molecular interactions 
Limonin -9.2 
A: H- A: Ser709, Lys714, Asp711, Thr710 
VDW: Gln773, Gly774, Asn781, Lys780, Ser784, His133, 
Lys47, Asn138, Tyr129, Asp135, Thr710, Tyr32 
Glycyrrhizinic acid -9.9 
A: H: Ser772, Tyr129, Asn781, Asn138 
VDW: Gln773, Lys714, Tyr32, Asp711, Ser784, Lys780, 
Gly774, Ser778, Ala706, Thr710, Asp135, His133, Cys139, 
Lys47 
7-deacetyl-7-benzoylgedunin -9.7 
A: H: Ser255 
VDW: Phe321,Pro323, Arg349, Pro677, THr246, Thr319, 
Thr252, Val320. π-π: Pro461, Tyr265, Arg249 
7-deacetylgedunin -8.8 
A: H: Lys780, Ser784, Asn781, C-H: Ala706, Gly774 
Asn138, Asp135, His133, Tyr129, Ser709, Ala706, Thr710, 
Lys47, Tyr32. π-π: Ala706 
Limonin17bDglucopyranoside -8.9 
A :H- His133, Ser784, Lys780, Ala706, Asp711 
C: Thr710, Gly774 
VDW- Asn138, Phe134, Ser709, Lys714, Ser772, Gln773, 
Asp135 
Obacunone -8.7 
A:C:Thr319, Thr252, VDW: Lys267, Tyr265, Arg249, Leu251, 
Ser255, Val320, Ile266, Phe321, Trp268, Pro323, Pro322 
 
3.4.4. Screening of inhibitors for SGp-RBD 
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The spike proteins determine the virion-host tropism that includes the entry of the virions 
into host cells, and their interactions with human ACE2. It constitutes the target prominent that 
plays a key role in the development of the procatylitics and therapeutics [50]. Two states in 
receptor binding domains (RBD) namely buried (lying state) or exposed (standing state) were 
observed in the recent reports coming up with structures of the different CoV’s that are 
inherently flexible with the RBD’s [50]. Due to its structural importance, we focused on SGp-
RBD inhibition study by screening 157 phytochemicals through molecular docking and binding 
confirmations at 3 active sites that could inhibit the SGp and hinder SGp-ACE2 complex 
formation. Spike glycoprotein RDB contains 333-527 residues where the active sites are located 
[51]. The molecular interactions between the best 6 phytochemicals with the SGp sites are shown 
in Table 5. 
Maslinic acid binding at the RBD where the initial contact was made towards ACE2. 
Maslinic acid with binding energy -9.3kcal/mol, forming a complex at C chain with a possible 
interactions to site-1: H bond to Arg441, non-covalent (VDW) interactions to Ser456, Leu443, 
Pro459, ly464, Lys465 and (Alkyl-π-alkyl) interactions to His445, Phe460, Arg444, Pro477, 
Pro466 (Fig. 4 and Fig. S7). It is also forming a complex at E chain site-2, H bond to Asp480, 
Tyr440 an unfavourable donor-donor interaction, Alkyl-π-alkyl to Tyr484, tyr491, Lys390 and 
VDW to Tyr436, Gly482, Thr486, Thr487, Asn479, Tyr481 (Fig. S8). In site-3, the maslinic acid 
binding to an active cavity at chain E residues Ser358, Ala331 forming H bond and non-covalent 
VDW interactions to Phe360, Asn427, Thr332, Asn424, Asn357, Thr359, Ile428, Trp423, 
Phe329, Tyr356, Thr425, Arg495, Asn330 (Fig. S9). Maslinic acid collectively forms 
hydrophobic interactions at site-1, site-2 and site-3 that could hinder the SpG-RBD complex with 
ACE2 host receptor. MD simulations of SpG-RBD complex generated the RMSF plot detailing 
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contact sites are showing the fluctuations in chain C: 432-438, 352-368, and 456-480, residues of 
receptor binding sites (Fig. S10). 
 
Fig. 4. (a) 2D animated pose between maslinic acid and SGp-RBD at site-1 showing various 
non-covalent interactions, (b) the corresponding 3D representation showing the position of 
maslinic acid within the hydrophobic cavity of SGp-RBD. 
The phytochemical corosolic acid showed maximum binding affinity (-9.4 kcal/mol) to 
site-3 of RBD residues Asn330, Phe334, Ala331, Phe329, Arg495, Trp423, Thr425, Thr359, 
Ser358, Phe360, Asn424, Asn427, Tyr356, Ile428, Thr332. Glycyrrhizic acid encapsulated at the 
active site-3 with B.E -9.3kcal/mol having H bond to Phe360, Arg426, Asn427, Trp423, Thr333 
and non-covalent VDW to Tyr356, Asn357, Ser358, Phe361, Ser362, Ile489, Gln492, Asn424, 
Thr359, Thr425, Arg495, Ile428, Asn330, Ala332 residues. 2-Hydroxyseneganolide and 
Gedunin binding to active sites of chain C residues with B.E -9.2 and -8.2kcal/mol respectively 
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to Trp423 and Gly368 by H bond. Oleanane binding to E chain active sites with closest non-
covalent VDW interaction to Thr332, Ala331, Tyr356 residues. 
 
Table 5. Screen phytochemicals used for protein-ligand interaction study against the SGp-RBD. 
Phytochemicals B.E. 
(Kcal/mole) 
Molecular interactions 
Maslinic acid -9.3 
C: H- Arg441 
VDW-Leu443, Asp454, Ser456, Pro459, Gly464, Lys465 
π-π:Phe460, His445, Arg444, Pro477, Pro466 
Corosolic acid  -9.4 
E:VDW-Asn330,Phe334,Ala331,Phe329,Arg495,Trp423, Thr425, 
Thr359,Ser358,Phe360,Asn424,Asn427,Tyr356,Ile428,Thr332 
Glycyrrhizic acid -9.3 
E: H: Phe360, Arg426,Asn427,Trp423, Thr333, C:Ser363 
VDW:Tyr356,Asn357,Ser358,Phe361,Ser362,Ile489,Gln492,Asn
424,Thr359,Thr425,Arg495,Ile428,Asn330,Ala332 
2-Hydroxyseneganolide -9.2 
C:H:Trp423,VDW:Asn330,Phe329,Thr359,Thr425,Asn427, 
Asn424,Ser358, Tyr356,Asn357,Thr332,Ala331,Arg495 
Oleanane -9.0 
E:VDW:Thr332,Ala331,Tyr356,Asn330,Phe329,Arg495, 
Trp423,Thr359,Asn424,Phe360,Ser358,Asn427,Thr425 
Gedunin -8.2 
C: H:Gly368, VDW: Asp415, Asp414, π-π:Pro399, Lys365, 
Ala398 
 
3.4.5. Screening of inhibitors for ACE2  
ACE2 plays a key role in cardio renal disease and acts as a human host receptor for the 
SARS and helps in viral-host interactions [52]. ACE2, a human viral receptor binds to SGp RBD 
at a specific site that establishes the primary contact for host-pathogen interaction [53]. The 
active site residues of ACE 2 were studied by using site-directed mutagenesis and it was found 
that Arg273 plays a critical role in substrate binding, whereas the consequence of its replacement 
results in the abolishment of the enzyme activity. Also, His 345 plays an important role as a 
hydrogen bond donor/acceptor to form the tetrahedral peptide intermediate [53]. From the 
computational approaches, the best 6 phytochemicals showing higher binding affinity at 
hydrophobic sites along with the molecular interactions are summarized in Table 6. 
Glycyrrhizic acid, the triterpenoid is showing better binding affinity (-10.3 kcal/mol) to 
RBD and ACE2 active sites. The receptor binding cavity interacts with glycyrrhizic acid through 
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Tyr202, Gln102, Ser106, Ser70 H-bonds, and Asp350, Trp349, Phe40, Tyr385, Arg393, Asn394, 
Trp69, Phe390, Leu391, Ala99, Leu73, Leu100, Lys74, Ser77, Asn103, Gly104 non-covalent 
VDW forces (Fig. 5 and Fig. S11).  Glycyrrhizic acid could potentially interfere with the SGp-
RBD-ACE2 complex formation. MD simulations of ACE2 complex with glycyrrhizic acid 
showing multiple contact sites. Some of the sites states SGp receptor forming a complex to 
ACE2 in host cells in receptor chain B: 51-81, 141, 201-231, 261, 321-351, 531-561, 591-651 
residues (Fig. S12). Out of these residues, the SpG-ACE2 initial contact take place in Q24, M82, 
L79, K31, H34, E37, G354, Q325, D38, N330, E 329, Q42, L45 residues. 
The phytochemicals ursolic acid, maslinic acid and obacunone showed comparable 
binding affinity to the ACE2. In case of ursolic acid, the hydrophobic cavity residues exhibit H 
bond to His493, and VDW forces to Lys475, Glu479, Arg482, Trp478, Tyr613, Glu489, 
Met474, Pro492, Glu495, Ala673, Asn674, Asp494 and Leu675 along with a C bond to Pro492. 
The interactions of other phytochemicals are summarized in Table 6. 
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Fig. 5. (a) 2D animated pose between glycyrrhizic acid and ACE2 showing various non-covalent 
interactions, (b) 3D representation showing the position of glycyrrhizic acid within the 
hydrophobic cavity of ACE2. 
Table 6. Screen phytochemicals used for protein-ligand interaction study against the ACE2. 
Phytochemicals B.E. 
(Kcal/mole) 
Molecular interactions 
Glycyrrhizinic acid -10.3 
B: H: Tyr202, Gln102, Ser106, Ser70 
VDW-Asp350,Trp349, Phe40, Tyr385, Arg393, Asn394, Trp69, 
Phe390, Leu391, Ala99, Leu73, Leu100, Lys74, Ser77, Asn103, 
Gly104 
Ursolic acid -10.2 
B: H: B: His493, C: B: Pro492 
VDW: Lys475, Glu479, Arg482, Trp478, Tyr613, Glu489, 
Met474, Pro492, Glu495, Ala673, Asn674, Asp494, Leu675 
Maslinic acid -10.2 
B: H: Asn674, Glu495, C: Asn674, Glu489, Asp494 
Arg482, Ser611, Tyr613, Trp478, Ala673, Pro492, His493, 
Val672, Met640, Leu675, Lys475, Glu479 
Obacunone -10.2 
B: VDW: Arg482, Glu479, Lys475, Asp471, Leu675, Asp494, 
Ala673, Pro492, Asn674, His493, Glu489, Tyr613 
Azadiradionolide -9.8 
B:VDW:Arg644, Val672, Leu675, Ala673, Asn674, Trp478, 
Lys475, His493, Met474, Asp494, Glu495, Thr496, Met640, 
Asp637, Arg644 
Gedunin -9.9 
B:Trp478, Glu479, Asn674, Lys475, Lys676, Glu495, Leu675, 
Asp494, Met640, His493, Pro492, Ala673, Glu489, Tyr613, 
Arg482, π-π - B: Val672 
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4. Conclusions 
In summary, the screening of 154 phytochemicals from limonoids and triterpenoids by 
molecular docking, in silico ADMET and drug likeness with five protein targets (3CLpro, PLpro, 
RdRp, SpG, ACE2) resulted 15 effective phytochemicals, from which best six phytochemicals 
were proposed as potential hits against the SARS-CoV-2. Among the six, the two neem isolates 
7-deacetyl-7-benzoylgedunin posing binding energy -9.1kcal/mol to cleave substrate binding site 
catalytic dyad residues (Cys145 and His41) of 3CLpro, a potential lead to inhibit proteases 
involved in the process of proteolysis of viral polyprotein into functional units and 
Epoxyazadiradione an active lead inhibiting the PLpro S2 subunit with -8.4kcal/mol binding 
energy to pocket consisting of Catalytic Triad (Cys112, His273, Asp287). A citrus fruit seed 
isolate limonin inhibiting the RdRp substrate binding site at NSP12-NSP7 residues with the B.E 
-9.2kcal/mol that inhibits the polymerase activity due to hindrance in NiRAM replication fork. 
Neem and Citrus fruits isolates potentially blocks the SARS-CoV-2 translation and replication 
functions. Maslinic acid, corosolic acid and 2-hydroxyseneganolide are potent inhibitors of SGp-
RBD active sites that hinder to dock hACE2 receptor. Glycyrrhizic acid including ursolic acid 
could potentially interfere with the ACE2-SGp RBD complex with binding energy -
10.3kcal/mol. Olives, holy basil and lycorice triterpenoids potentially obstruct SGp and ACE2 
receptors disease establishment. Therefore, the computational predictions along with the reported 
pharmacological properties postulated that the limonoids and triterpenoids are potential against 
SARS-CoV-2 target proteins.  The outcomes will be useful in formulating therapeutic strategies 
using the traditional medicines as well as the potential hits can be used for lead optimization for 
drugs discovery for SARS-CoV-2. 
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